[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The George Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":384},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,46,71,98,129,155,177,200,228,250,283,310,335,357],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100374574","essential-acute-stroke-care-in-low-resource-settings-a-pilot-study-100374574",false,"NCT04157231","Essential Acute Stroke Care in Low Resource Settings: a Pilot studY","Essential Acute Stroke Care in Low Resource Settings: a Pilot Study","EASY","Inclusion Criteria:\n\n* Adults (age ≥18 years)\n* A clinical or imaging-based diagnosis of acute stroke (ischemic or haemorrhagic) within 72 hours of stroke symptom onset\n* Provision of written informed consent\n* Subjects in observational, natural history and\u002For epidemiological studies not involving an intervention are eligible.\n\nExclusion Criteria:\n\n* Patients who have undergone intravenous thrombolysis or mechanical thrombectomy\n* Patients who are planned for transfer to the intensive care unit\n* Subarachnoid haemorrhage\n* Participation in an interventional medical investigation or clinical trial currently or within the past 3 months.","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","An investigator-initiated, evaluator-blinded, prospective, multi centre, before-and-after, effectiveness-implementation hybrid design study to assess the feasibility of essential acute stroke care in a low resource setting",[27],"Acute Stroke",[29,30,31,32],"Stroke","Ischemic stroke","hemorrhagic stroke","stroke package","NOT_YET_RECRUITING","2026-06-09",{"date":36,"type":37},"2026-06-11","ACTUAL",{"date":39,"type":21},"2027-12-30",{"date":41,"type":21},"2030-12-30",{"name":43,"class":44},"The George Institute","OTHER",4,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100537511","phase-4-comparative-effectiveness-study-of-two-forms-of-ketamine-for-treatment-resistant-depression-100537511","NCT06278779","Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression","Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-Resistant Depression: a Randomised, Rater-blinded Trial","TREK","Inclusion Criteria:\n\n* Adult with treatment-resistant depression (TRD: not responded adequately to at least two different antidepressants of adequate dose and duration) who has a current depressive episode (DSM 5)\n* Assessed and attested by clinic psychiatrist as appropriate to receive either racemic ketamine or Spravato® ketamine treatment for TRD\n* MADRS score of ≥20 at study baseline, assessed by certified study rater\n* Aged ≥18 years\n* Written informed consent for research study obtained\n\nExclusion Criteria:\n\n* Not able to give informed consent\n* Any physical or mental condition which, in the opinion of the investigator, could interfere with study participation including outcome assessments\n* Any treatment with ketamine or Spravato® within 4 weeks prior to written informed consent for the research study\n* Patients who require an interpreter\u002Ftranslator for the clinic consent process, due to the infeasibility of obtaining an interpreter for research assessments, including self-rated scales",{"count":55,"type":21},162,[57],"PHASE4","The goal of this study is to compare the effectiveness of two formulations of ketamine - Spravato® and racemic ketamine - in people with treatment-resistant depression (TRD). The main questions it aims to answer are:\n\n* How the two formulations compare in terms of their effectiveness in treating TRD.\n* How the two formulations compare in their acceptability to patients, safety, effects on patient quality of life and function, and cost effectiveness.\n\nParticipants will be randomised to receive either Spravato® or racemic ketamine treatment and asked to complete some questionnaires to assess the effects on mood, treatment acceptability, side effects, quality of life and function, and health economic outcomes.",[60],"Treatment Resistant Depression","RECRUITING","2026-05-27",{"date":64,"type":37},"2026-05-29",{"date":66,"type":37},"2024-06-03",{"date":68,"type":21},"2027-04",{"name":43,"class":44},7,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100520593","phase-3-the-chronic-kidney-disease-adaptive-platform-trial-investigating-various-agents-for-therapeutic-effect-100520593","NCT06058585","The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect","CAPTIVATE","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Known chronic kidney disease from any cause (eGFR ≥25 mL\u002Fmin\u002F1.73m2)\n3. Currently receiving standard of care treatment according to treating physician\n4. Eligible for randomisation in at least one recruiting domain-specific appendix\n5. Participant and treating physician are willing and able to perform trial procedures\n\nExclusion Criteria:\n\n1. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months\n2. Life expectancy less than 6 months",{"count":79,"type":21},1000,[81],"PHASE3","CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).\n\nCAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.\n\nCAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.",[84],"Chronic Kidney Diseases",[86,87,88],"Chronic kidney disease","Mineralocorticoid Receptor Antagonist","Finerenone","2026-03-26",{"date":91,"type":37},"2026-04-01",{"date":93,"type":37},"2024-09-04",{"date":95,"type":21},"2029-03-31",{"name":43,"class":44},43,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":118,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100579076","phase-3-prophylaxis-against-early-ventilator-associated-infections-in-acute-brain-injury-100579076","NCT06819592","PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury","PRophylaxis Against Early VENTilator-associated Infections to Reduce Mortality in Mechanically Ventilated Intensive Care Unit (ICU) Patients With Acute Brain Injuries: a Phase 3 Randomised, Double Blind, Parallel Group, Placebo-controlled Two-side Superiority Trial","PREVENT-NEURO","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Receiving invasive mechanical ventilation\n3. The requirement for mechanical ventilation is because of an acute brain injury due to intracranial haemorrhage, ischaemic stroke, cerebral venous sinus thrombosis, subarachnoid haemorrhage, suspected hypoxic ischaemic encephalopathy post cardiac arrest, or traumatic brain injury.\n4. Admitted to an ICU or is anticipated to be admitted to an ICU\n\nExclusion Criteria:\n\n1. Endotracheal intubation was more than 12 hours ago\n2. Hospital admission was more than 72 hours ago\n3. Anticipated inability to deliver trial intervention within 90 minutes of randomisation\n4. Documented use of antibiotic therapy in the week prior to hospitalisation\n5. Currently receiving antibiotic therapy, or intention to prescribe antibiotic therapy, excluding cephazolin for peri-operative prophylaxis\n6. Any contraindication to receiving ceftriaxone\n7. Known or suspected pregnancy\n8. Death within 90 days is deemed inevitable due to the current illness or intercurrent medical conditions\n9. Previously enrolled in the PREVENT-NEURO trial.",{"count":107,"type":21},3300,[81],"This research is about whether treatment with a commonly used antibiotic can prevent infections in airway and lungs and improves the chance of surviving, if it is given soon after patients commence mechanical ventilation when they have been admitted to hospital with an acute severe brain injury.\n\nAn acute severe brain injury can occur as a result of a stroke, a traumatic injury or due to lack of oxygen to the brain that happens as a result of a cardiac arrest.\n\nPatients who are unconscious after an acute severe brain injury often need assistance to breath adequately, and this assistance is given by a breathing tube, connected to a mechanical ventilator. This treatment is an emergency medical treatment. The breathing tube is inserted into the patients' airway by either their mouth or neck. For patients who need assistance with their breathing from a mechanical ventilator, infections in the airways and lungs, known as pneumonia, are a common complication. Everyone naturally has bacteria in their mouth, esophagus and stomach. Clinicians think that during the process of inserting the breathing tube, small amounts of these bacteria can be introduced into the airways and lung when people are unconscious following an acute severe brain injury, or during the process of placing the breathing tube into the airways. These bacteria are now in a place they aren't meant to be and can cause an infections in the airways and lungs known as pneumonia.\n\nThe purpose of this research is to see if giving one dose of a common antibiotic can prevent patients developing pneumonia, which is associated with having a breathing tube inserted and being on a ventilator, improving the chance of recovery following the acute severe brain injury and ultimately improving the chance of surviving.\n\nWhen patients have a known infection, current guidelines are to treat them with antibiotics. Antibiotics work to kill the bacteria causing the infection. When a patient has an infection in their lungs, they often need to stay on the mechanical ventilator for longer. While current practice is to give patients with a proven infection in their airways and lungs (pneumonia) antibiotics, it is unknown if giving an antibiotic to patients to prevent these infections before they show signs of pneumonia may lead to better outcomes.",[111,112,113,114,115,116,117],"All-cause Mortality","Quality of Life","Disability, Intellectual","Neurological Disorder","Acute Brain Injury","Ventilation, Mechanical","Intensive Care Medicine",[115,119],"Mechanical Ventilation","2026-02-16",{"date":122,"type":37},"2026-02-19",{"date":124,"type":37},"2025-10-30",{"date":126,"type":21},"2029-12",{"name":43,"class":44},9,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100547545","phase-2-fludrocortisone-administration-in-aneurysmal-subarachnoid-haemorrhage-100547545","NCT06409364","FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage","A Prospective, Blinded, Randomised Clinical Trial of Fludrocortisone Compared With Placebo in Critically Ill Patients Presenting With Aneurysmal Subarachnoid Haemorrhage","FLASH","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Diagnosed with subarachnoid haemorrhage from an aneurysm confirmed on computed tomography angiography (CTA) or digital subtraction angiography (DSA) of the intra-cranial arteries\n3. Aneurysm has been secured\n4. Hospital admission for aSAH within 96 hours\n5. Currently being treated in a critical care environment\n\nExclusion Criteria:\n\n1. Unable to receive enteral medications\n2. Pre-existing glucocorticoid or mineralocorticoid treatment\n3. Previous allergic reaction to fludrocortisone\n4. History of cardiac, hepatic, or renal failure\n5. Hypernatremia or hyponatremia (Na\\>145mmol\u002FL or Na\\\u003C125mmol\u002FL) on the most recent blood sample at the time of screening.\n6. Death deemed imminent or inevitable\n7. Pregnancy (confirmed or suspected)\n8. Previous inclusion in the FLASH trial",{"count":138,"type":21},524,[140],"PHASE2","A multi-centre, prospective, blinded, randomised clinical trial of fludrocortisone compared with placebo in patients presenting with aneurysmal subarachnoid haemorrhage.\n\nThe study aim is to determine if early administration of enteral fludrocortisone in aneurysmal subarachnoid haemorrhage reduce death and dependency at six months.",[143],"Aneurysmal Subarachnoid Hemorrhage",[145],"aSAH","2025-12-08",{"date":148,"type":37},"2025-12-16",{"date":150,"type":37},"2025-08-13",{"date":152,"type":21},"2030-07-31",{"name":43,"class":44},16,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":165,"phases":4,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":45},"100610725","interact4-expansion---validation-study-100610725","NCT07231315","INTERACT4 Expansion - Validation Study","INTEnsive Ambulance-delivered Blood Pressure Reduction in Biomarker-identified Hyper-ACute Intracerebral Haemorrhage Trial - Validation Study","INTERACT4 Exp","Inclusion Criteria:\n\n1. Adults (age ≥18 years);\n2. Acute syndrome that is due to presumed acute stroke, defined as FAST (Face, Arm, Speech, Time) scores of ≥2 with an arm motor deficit;\n3. Time ≤3 hours from last seen well;\n4. Systolic BP (SBP) ≥150mmHg.\n\nExclusion Criteria:\n\n1. Participants in coma (no response to tactile\u002Fverbal stimulation); or\u002Fand do not respond to \"P\" or \"U\" on the alert\u002Fverbal\u002Fpainful\u002Funresponsive (APVU) responsiveness scale;\n2. Severe known co-morbid disease (e.g. cancer, chronic airflow disease, severe dementia, severe heart failure, pre-existing disability \\[needing help\\]);\n3. Known history of epilepsy or seizure at onset;\n4. Recent head injury (where there is potential for another type of intracranial haemorrhage or head trauma);\n5. Hypoglycaemia (glucose\\\u003C4.0 mmol\u002FL) as measured in the ambulance.",{"count":164,"type":21},465,"OBSERVATIONAL","As an investigator-initiated and conducted, multi-centre, open-label, single-arm prospective observational trial, INTERACT4 Expansion aims to evaluate the diagnostic accuracy of GFAP measured using a point-of-care device, for identifying ICH in participants presenting with acute stroke-like symptoms in the pre-hospital setting compared with imaging-confirmed ICH.",[168],"Intracerebral Hemorrhage","2025-11-17",{"date":171,"type":37},"2025-11-19",{"date":173,"type":21},"2026-02-01",{"date":175,"type":21},"2027-06-01",{"name":43,"class":44},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},"100497056","phase-3-balanced-multi-electrolyte-solution-versus-saline-trial-for-diabetic-ketoacidosis-100497056","NCT05752279","Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis","Balanced Multi-electrolyte Solution Versus 0.9% Sodium Chloride as Fluid Therapy for Patients Presenting With Moderate to Severe Diabetic Ketoacidosis","BEST-DKA","Inclusion Criteria:\n\n* Patients in the ED with a primary diagnosis of moderate to severe DKA for whom both saline and Plasma-Lyte® 148 are considered appropriate fluids\n* Blood glucose level \\> 14mmol\u002FL\n* pH \\\u003C 7.25\n* Serum bicarbonate \\\u003C15 mmol\u002FL\n* Elevated anion gap \\> 12mEq\u002FL\n* Ketones positive on finger prick measurements\n* In the judgement of the treating clinician critical care area admission is required\n\nExclusion Criteria:\n\n* Age less than 18 years\n* Patients who have received more than 2000ml of non study fluid prior to study enrolment\n* Serum Na \\> 155 or \\\u003C120 mmol\u002FL\n* Contraindication to either study fluid e.g. previous allergic reaction to Plasma-Lyte® 148\n* Patients with hyperosmotic hyperglycaemic non-ketotic syndrome\n* Other clinical conditions that preclude large volumes of fluid resuscitation\n* Previous inclusion in BEST-DKA trial",{"count":186,"type":21},680,[81],"The goal of this blinded, cluster cross-over, randomised controlled trial is to determine whether fluid therapy with Plasma-Lyte® 148 increases the number of days alive and days out of hospital to day-28 compared to 0.9% sodium chloride ('0.9% saline') in critically ill patients presenting to the Emergency Department (ED) and deemed to require admission to a critical care area (ICU, HDU) with moderate to severe diabetic ketoacidosis (DKA).",[190],"Diabetic Ketoacidosis","2025-09-10",{"date":193,"type":37},"2025-09-17",{"date":195,"type":37},"2024-03-14",{"date":197,"type":21},"2026-07",{"name":43,"class":44},21,{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":208,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":227},"100499806","trial-of-enhanced-neurostimulation-for-anorexia-100499806","NCT05788042","Trial of Enhanced Neurostimulation for Anorexia","Randomised Controlled Trial of Neurostimulation for Symptoms of Anorexia Nervosa","TRENA","Inclusion Criteria:\n\n* Aged ≥16 years,\n* A current Diagnostic and Statistical Manual of Mental Disorders (5th edition DSM-5) diagnosis of anorexia nervosa\n* Willing and able to participate and comply with study requirements\n* Worked or studied in a context requiring some proficiency in spoken English (to ensure validity of neuropsychological testing)\n* Under ongoing care by his\u002Fher own treating psychiatrist (to ensure patient safety during the study)\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Contraindications to tDCS\u002FrTMS\n* Failed to respond to an adequate course or rTMS (4 weeks) within the current illness course\n* Had ECT in the last 3 months\n* MoCA score of \\\u003C26\n* Significant risk of significant self harm or suicide as assessed by study psychiatrist(s)\n* Currently enrolled in another interventional clinical trial or using an investigational device\u002Fproduct","16 Years",{"count":210,"type":21},70,[24],"Preliminary open-label studies have suggested that non-invasive brain stimulation methods of both transcranial direct current stimulation (tDCS) and repetitive transcranial magnetic stimulation (rTMS) have clinical benefits for improving psychological and eating disorder related symptoms, which can persist at long-term follow ups after acute treatment (i.e., at 6 and 12 months).\n\nHere the investigators propose to conduct the first double-blinded, randomised sham-controlled study to directly compare the therapeutic effectiveness and acceptability of both treatment modalities.\n\nParticipants will be recruited and treated at one inpatient setting (Northside Clinic, St Leonards, Sydney). This facility is one of the largest specialist eating disorder settings in Australia with approximately 130 new admissions every year (2019 data). All participants who give consent and who fulfill the eligibility criteria will be randomised to receive active tDCS, sham (placebo) tDCS, active rTMS or sham rTMS over 8 weeks. Trial participants, their treating psychiatrist, ward staff, and a study staff member (who will conduct blinded assessments of mood secondary outcome measures) will be blinded after assignment to intervention until the database is locked and the primary analysis completed. All participants will complete assessments of eating disorder symptoms, mood, psychological symptoms, neurocognition and functioning at baseline, end of week 4, 8 and 20.\n\nExpected outcomes include data on the relative effectiveness and acceptability for both treatment modalities in the inpatient and at-home setting (i.e., for at-home tDCS). The investigators expect that both active treatment arms will produce clinical benefits and have high acceptability, and that clinical benefits will be maintained with long-term at-home tDCS continuation treatment. These outcomes have potential to assist in reducing hospital stay and emergency re-admissions and improving day to day functioning in participants. Health economic data for both treatment modalities will additionally have utility from a service perspective, given the disparity in resource requirements between the two treatments (TMS, tDCS) in terms of costs for patients and access to treatment for people living in remote and rural areas (i.e., for at-home tDCS).",[214],"Anorexia Nervosa",[214,216,217,218],"Repetitive Transcranial Magnetic Stimulation","Transcranial Direct Current Stimulation","Non-invasive brain stimulation","2025-09-05",{"date":221,"type":37},"2025-09-12",{"date":223,"type":37},"2023-08-02",{"date":225,"type":21},"2026-04-30",{"name":43,"class":44},1,{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":227},"100588005","optimised-treatment-for-hypertension-trial-100588005","NCT06935760","Optimised Treatment for Hypertension Trial","Optimised Treatment for Hypertension Trial - A Feasibility and Pilot Trial of Fire and Forget Versus Usual Care With Intensive Blood Pressure Monitoring for Optimal Hypertension Care","OPTIMISE-BP","Inclusion Criteria:\n\n* Written Informed consent\n* Adult aged ≥18 years\n* English proficiency\n* High BP defined as home SBP ≥135 or DBP ≥85 mmHg, either untreated or receiving one or two BP lowering drugs\n* Among untreated individuals, indicated for pharmacological treatment of high BP according to 2023 Australian Heart Foundation Cardiovascular Risk Management Guidelines\n* Willing to receive BP lowering drug treatment remotely if treatment is indicated\n* Willing to check BP with home monitoring for 12 weeks\n* Willing to participate in telehealth visit at baseline and 12 weeks\n* Willing to undergo blood tests\n\nExclusion Criteria:\n\n* Currently receiving three or more BP lowering drugs\n* Currently receiving an antihypertensive that is not one of the five major antihypertensive drug classes\n* Home SBP ≥155 mmHg for untreated participants\n* Home SBP ≥150 mmHg for participants on one BP lowering drug\n* Home SBP ≥145 mmHg for participants on two BP lowering drugs\n* Baseline eGFR \\\u003C45 ml\u002Fmin\u002Fm2\n* Any abnormalities on baseline electrolytes that would prevent initiation of BP lowering therapy\n* Participants with any other medical condition or taking any other concomitant medication which in the opinion of the investigator would make the participant unsuitable for the trial.\n* Of childbearing age and not using contraception.\n* Planned international travel for next 12 weeks",{"count":237,"type":21},120,[24],"This randomized trial compares two prescribing strategies to treat high blood pressure. One approach involves remote treatment informed by randomized trial evidence without regular monitoring of blood pressure (\"fire and forget\"), whilst the other involves usual care treatment with access to frequent blood pressure monitoring. The study will enrol participants with uncontrolled high blood pressure and randomize participants 1:1 to a \"fire and forget\" treatment group or a \"more blood pressure monitoring\" group for a total of 12 weeks. \"Fire and forget\" involves choosing the most appropriate treatment based on the highest quality evidence (randomized trial data), after which participants will stop measuring blood pressures until the end of study. The \"more blood pressure monitoring\" group will involve treatment as usual but with the access to frequent and high quality blood pressure monitoring.\n\nThe goal of this research is to:\n\n1. determine which prescribing approach is more effective at lowering blood pressure after 12 weeks (end of study)\n2. assess the safety, feasibility and acceptability of the two treatment approaches.",[241],"Hypertension","2025-08-17",{"date":244,"type":37},"2025-08-21",{"date":246,"type":21},"2025-08-28",{"date":248,"type":21},"2026-12-30",{"name":43,"class":44},{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":261,"conditions":262,"keywords":266,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":282},"100574728","phase-3-the-fifth-intensive-preventing-secondary-injury-in-acute-cerebral-haemorrhage-trial-within-act-global-100574728","NCT06763055","The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL","INTERACT5","Inclusion Criteria:\n\n1. Age between 18 and 80 years old\n2. Diagnosis of presumed spontaneous supratentorial intracerebral haemorrhage, confirmed by brain imaging\n3. Presentation to hospital within 24 hours of symptom onset (or last seen well)\n4. Hematoma volume ≥10 mL or any volume post-surgery\n5. NIHSS score \\>8\n6. GCS ≥8\n7. Provide written informed consent by patient (or approved surrogate)\n\nExclusion Criteria:\n\n1. Secondary cause of haemorrhage (e.g., structural abnormality such as arteriovenous malformation, cerebral aneurysm, tumour, trauma), or haemorrhagic transformation of acute ischaemic stroke\n2. Isolate intraventricular haemorrhage\n3. Chronic Kidney Disease\n4. Very high likelihood of death within 7 days or poor adherence to study treatment or follow-up\n5. Severe comorbid disease that will interfere with outcome assessments (e.g., cancer, chronic airflow disease, heart failure, significant disability)\n6. Women who are pregnant or lactating\n\n   Exclusion Criteria related to use of deferoxamine:\n7. Previous chelation therapy or known hypersensitivity to deferoxamine products;\n8. Severe iron deficiency anaemia (haemoglobin \\\u003C7 g\u002FdL or requiring regular blood transfusions);\n9. Taking iron supplements containing \\>325 mg of ferrous iron;\n10. Serum creatinine \\>2 mg\u002FdL;\n11. Patients with known heart failure taking \\>500 mg of vitamin C\n\n    Exclusion criteria related to the use of colchicine:\n12. Allergic to colchicine\n13. Myelodysplastic hypoplasia, or liver or severe renal failure\n14. Use of medication which may interact with colchicine (e.g., strong CYPsA4 inhibitors such as ketoconazole, strong P-glycoprotein inhibitors such as fluconazole)","80 Years",{"count":259,"type":21},2000,[81],"This is a domain within the ACT-GLOBAL platform trial to compare the effectiveness of early and appropriate pharmacological interventions in acute intracerebral hemorrhage (ICH) to control secondary brain injury. Up to 2000 patients with presumed spontaneous supratentorial intracerebral hemorrhage (ICH) will be followed for 6 months (or death, if prior to 6 months).\n\nAdaptive interim analyses will be used, with statistical triggers to determine if any of the interventions are superior to control. The end of the trial is defined as the date that all participants have completed their 6-month assessment.\n\nA large amount of preclinical data indicates that the outcome from ICH is linked to the detrimental effects of breakdown substances from brain bleeds. However, there remains a lack of compelling evidence supporting the effectiveness of any pharmacological intervention that can mitigate the secondary cerebral injury. The INTERACT domain aims to assess the effectiveness of intravenous deferoxamine and low-dose oral colchicine, both individually and in combination, to standard of care alone, on improving functional outcome in patients with spontaneous supratentorial ICH.\n\nThose patients who meet eligibility criteria will be randomized to receive one of four interventions:\n\n1. No deferoxamine mesylate and no colchicine (labeled as control)\n2. Deferoxamine mesylate only: deferoxamine mesylate at a dose of 32mg\u002Fkg\u002Fday via intravenous infusion immediately (within 1 hour) post-randomization and continue for the following 2 consecutive days.\n3. Colchicine only: 0.5mg of oral colchicine daily for 30 consecutive days.\n4. Both deferoxamine mesylate and colchicine: deferoxamine mesylate at a dose of 32mg\u002Fkg\u002Fday via intravenous infusion immediately (within 1 hour) post-randomization and continue for the following 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days.",[168,263,264,265,27],"Spontaneous Intracerebral Hemorrhage","Supratentorial Intracerebral Haemorrhage","Acute Intracerebral Haemorrhage",[29,27,267,168,268,269,270,271,272,273],"ICH","Platform Trial","Adaptive Platform Trial","Supratentorial ICH","secondary brain injury","deferoxamine mesylate","colchicine","2025-04-08",{"date":276,"type":37},"2025-04-10",{"date":278,"type":37},"2025-02-27",{"date":280,"type":21},"2028-01",{"name":43,"class":44},2,{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":309},"100465792","phase-3-sglt2-inhibitors-as-first-line-therapy-to-prevent-renal-decline-in-type-2-diabetes-100465792","NCT05345327","SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes","START","Inclusion Criteria:\n\n* Diagnosis of T2D;\n* Aged ≥18 years;\n* Body mass index \\> 18.5 kg\u002Fm2;\n* Drug naïve, or managed with metformin monotherapy and willing to be randomised to either dapagliflozin or metformin;\n* eGFR ≥45 ml\u002Fmin\u002F1,73m2; and\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Have an immediate need for rapid intensification of glucose lowering therapy due to marked hyperglycaemia; or\n* There is a definite indication for, or contraindication to, either metformin or SGLT2 inhibitor; or\n* They have clearly documented coronary artery disease (defined as a previous acute coronary syndrome, coronary stent or bypass surgery) or clearly documented heart failure (defined on the basis of a hospital admission, specialist diagnosis or an echocardiogram or other imaging modality); or\n* Pregnant or breast-feeding.",{"count":291,"type":21},994,[81],"The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.",[295],"Type 2 Diabetes",[297,298,299,300],"Diabetes","Renal decline","Metformin","Sodium Glucose Co-Transporter 2 inhibitor","2024-12-17",{"date":303,"type":37},"2024-12-20",{"date":305,"type":37},"2023-01-01",{"date":307,"type":21},"2026-06-30",{"name":43,"class":44},8,{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":282},"100543188","third-enhanced-control-of-hypertension-and-thrombectomy-stroke-domain-within-act-global-adaptive-platform-trial-100543188","NCT06352619","Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial","Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL_ENCHANTED3\u002FMT)","ENCHANTED3\u002FMT","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Use of endovascular therapy (EVT) within 24 hours of symptom onset or last known well according to local guidelines;\n3. Sustained high systolic blood pressure ≥150 mmHg (2 readings \\\u003C10 mins apart) within 3 hours after completion of EVT.\n\nExclusion Criteria:\n\n1.Any definite contraindications to BP lowering treatment.",{"count":259,"type":21},[24],"Several clinical trials have produced variable conclusions regarding the effects of intensive blood pressure (BP) lowering in post-EVT acute ischaemic stroke (AIS) patients. Although two trials indicate harm from very intensive target-based treatment (SBP \\\u003C130 mmHg), the others neutral effects in the SBP range 140-160 mmHg. The ENCHANTED3\u002FMT domain of the ACT-GLOBAL platform trial aims to test different approaches to the treatment of elevated SBP in post-EVT AIS patients to find an optimal BP management strategy. ENCHANTED3\u002FMT will randomize (1:1:1) up to 2,000 patients with SBP ≥150 mmHg post-EVT to conservative (no or minimal SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP \\[≥180mmHg\\]), moderate (SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP \\[150-160mmHg\\]), or intensive (SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher) BP management.",[322],"Ischemic Stroke, Acute",[324,325,326],"Blood Pressure","Endovascular Therapy","Ischemic Stroke","2024-11-18",{"date":329,"type":37},"2024-11-21",{"date":331,"type":37},"2024-10-11",{"date":333,"type":21},"2026-05",{"name":43,"class":44},{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":22,"phases":344,"briefSummary":345,"conditions":346,"keywords":347,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":282},"100543189","phase-3-act-global-adaptive-platform-trial-for-stroke-100543189","NCT06352632","ACT-GLOBAL Adaptive Platform Trial for Stroke","A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL)","Platform Inclusion Criteria:\n\n1. Age ≥18 years\n2. Clinical diagnosis of stroke\n\nPlatform Exclusion Criteria:\n\nThere are no platform level exclusion criteria\n\nEach state and domain will specify additional inclusion and exclusion criteria in the respective Domain-Specific Registration. Patients who fulfill the overall platform criteria will be assessed for enrollment into each active domain.",{"count":343,"type":21},20000,[81],"Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment\u002Fs associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.",[29],[269,324,348,349,350],"Tenecteplase","Ischaemic stroke","Intracerebral Haemorrhage",{"date":329,"type":37},{"date":353,"type":37},"2024-09-26",{"date":355,"type":21},"2034-09",{"name":43,"class":44},{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":368,"conditions":369,"keywords":373,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":381,"leadSponsor":383,"locationsCount":227},"100559049","phase-3-ultra-early-statin-in-patients-with-aneurysmal-subarachnoid-hemorrhage-ue-star-100559049","NCT06559072","Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR)","Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR): a Randomized Controlled Trial","Ue-STAR","Inclusion Criteria:\n\n1. Male or female; Aged ≥18 years\n2. Signs and symptoms presumed aneurysmal subarachnoid hemorrhage, confirmed by radiological evidence\n3. Treatment within 6 h after symptom onset\n\nExclusion Criteria:\n\n1. Treatment with statin prior SAH\n2. Non-aSAH (e.g. traumatic subarachnoid hemorrhage, arteriovenous malformation)\n3. Treatment \\> 6 h after symptom onset\n4. Allergy to statin medications or presence of severe adverse reactions such as abnormal liver function or rhabdomyolysis\n5. Evidence of irreversible brain damage or expected death within 7 days\n6. Known severe liver or kidney disease\n7. Non-compliance with follow-up\n8. Pregnant or breastfeeding\n9. History of severe cranial or psychiatric illness\n10. Concomitant serious systemic disease\n11. Patients with malignant tumors\n12. Currently participating in another clinical trial\n13. Considered unsuitable for the clinical trial by clinical physicians or researchers",{"count":366,"type":21},522,[81],"A researcher-initiated and conducted multicenter, randomized controlled trial aimed at evaluating the efficacy and safety of ultra-early statin therapy in the treatment of acute aneurysmal subarachnoid hemorrhage (aSAH).",[370,371,143,372],"Subarachnoid Hemorrhage","Subarachnoid Hemorrhage, Aneurysmal","Hemorrhage, Aneurysmal Subarachnoid",[374,375,376],"aneurysmal subarachnoid hemorrhage","atorvastatin","Atorvastatin Calcium","2024-09-01",{"date":379,"type":37},"2024-09-05",{"date":377,"type":21},{"date":382,"type":21},"2026-09-01",{"name":43,"class":44},""]